We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...

A French pharmaceutical giant is acquiring a biotech and its rare immunology disease treatment which is already approved in ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

Paris: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in ...

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...

As part of a strategy to strengthen its immunology segment through acquisitions, Sanofi has agreed to buy US-based Blueprint ...

Sanofi has agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the company aims to expand the company's ...